Tempest Therapeutics, Inc. (TPST) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Brisbane, CA, United States. The current CEO is Matthew Angel.
TPST has IPO date of 2012-11-12, 24 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $9.99M.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
